Ma Yinglong Pharmaceutical Group Co., Ltd. (600993)

Ma Yinglong Pharmaceutical Group Co., Ltd. (600993)

Mayinglong [600993] is a stock issued by Mayinglong Pharmaceutical Group Co., Ltd[ 1]

Key points 1: QFII heavy warehouse plate, biological vaccine plate, China Securities 500 plate, Shanghai Securities 380 plate, Shanghai Stock connect plate, certificate fund holding plate, private hospital plate, Hubei plate, pharmaceutical manufacturing plate, social security warehouse plate, financing and securities trading plate, and traditional Chinese medicine plate.

Key point 2: the main business scope is to manufacture Chinese and Western medicine; The enterprise operates the export business of its own products and related technologies; To import raw and auxiliary materials, machinery and equipment, instruments, spare parts and related technologies required by the production and research of the enterprise; To operate the feed processing and "three supplies and one supplement" business of the enterprise; Plastic bottles, cosmetics, pharmaceutical machinery manufacturing, processing, sales; Freight by car. The company is one of the largest hemorrhoids manufacturers in China. Its market share of hemorrhoids in OTC market remains more than 50%, and the market share is 26%. The company was rated as the "top 500 valuable brand in China" in 2007, with a brand value of 3.172 billion yuan, ranking 218; It was selected as the first batch of 300 "national key protection brands" by China Brand Research Institute.

Key point 3: Zhizhi pharmaceutical company is one of the largest hemorrhoids pharmaceutical manufacturers in China. Its predecessor is Mayinglong Shengji drugstore founded in Wanli period of Ming Dynasty (i.e. 1582 A.D.), and has been an old pharmaceutical enterprise with a history of more than 400 years. The market share of hemorrhoids in OTC market is still over 50%, and the market share is 26%. Among them, Musk Hemorrhoids cream basically monopolizes the market of this dosage form, and the market share in OTC market is over 80% and its sales scale has the potential to increase. The new products of hemorrhoids are diosming tablet, Zhiyan xiaopian, Jinxuan hemorrhoids fumigant, polyethylene glycol 4000 powder are listed and sold successively, and the structure of series products of anal and intestinal hemorrhoids is basically formed.

Key points 4: the high market share of hemorrhoids in domestic market, the demand for cough drugs is large, while the company's main products, such as maxinglong Musk Hemorrhoids Ointment and compound licorice mixture, are of good quality, high market popularity, moderate price, remarkable curative effect and strong market competitiveness. The company's two major products for hemorrhoids, Diosmin raw materials and tablets, were approved in july2006. Jinxuan hemorrhoids fumigant, polyethylene glycol 4000 powder, gynecology products, were approved by the State Drug Administration, and the gynecology products cyclopyruvamide vaginal suppository obtained the production approval of the State Drug Administration, and morphine sulfate suppository was approved by the State Drug Administration. In addition, the company plans to establish 5-8 chain anal and intestinal hospitals in the country for 8-10 years.

Key point 5: the brand advantage of traditional Chinese medicine, Ma Yinglong Longzhu ointment product is transformed from the family secret recipe of Mayinglong family. In clinical stage, the supply is short of demand due to the good effect (the drug cost of dermatosis in China is about 600 million yuan per year). Ma Yinglong has been listed in the national key protection brand list. The old Chinese brand and the well-known trademark image of China have been widely recognized. The company has become the only "China famous trademark" in the field of hemorrhoids in China. In the latest published list of China's 500 most valuable brands in 2010 issued by the world brand laboratory, Ma Yinglong has been selected for seven consecutive years with a brand value of 4.321 billion yuan, The position and value have been improved year by year. In june2011, the company's "Mayinglong eye medicine production technology" was selected into the third batch of national intangible cultural heritage list.

Key point 6: the enterprise aims to further expand the chain drugstores of Wuhan Mayinglong pharmacy chain Co., Ltd. and plans to use the methods of acquisition and merger and asset restructuring to make its chain drugstores expand rapidly in quantity, and make Mayinglong pharmacy the first brand of the direct store recognized in Wuhan industry, with 120 Direct stores. Guanfu - 1, a national innovative drug, has been involved in cardiovascular field.

Key 7: the chain operation mode of anorectal Hospital of the company has been formed, and Nanjing anal and intestinal hospital is under construction. Previously, Wuhan Mayinglong anal bowel hospital (with an investment of 15 million yuan accounting for 100%) invested by Wuhan Mayinglong hospital investment company (45 million yuan accounted for 97.78%) was put into operation on December 28, 2008. The hospital was built according to the national third level hospital standard, and the software and hardware conditions reached the first-class level in China.

Key 8: the independent price increase right increased 15% after the end of 2007. The factory price of its leading products was increased again in June 2009. The settlement price of supply and settlement of the leading product, maxinglong Musk Hemorrhoids Ointment, rose 8.7%. The highest market sales price approved by the provincial price department obtained by the company has been increased from 5.7 yuan to 9.8 yuan for each previous payment. The price sales space of about 20% owned by the dealers in the past has been greatly increased to 96%, which will stimulate the sales enthusiasm of dealers, and also means that the factory price of the company still has room for improvement.

Key 9: Musk Hemorrhoids cream was officially issued on August 18, 2009 in the national basic drug catalogue of new medical insurance. Among more than 100 Chinese patent medicines, the exclusive varieties accounted for more than 20%. The company and its subsidiaries have 18 Chinese medicine quasi brand varieties, such as Mayinglong Musk Hemorrhoids Ointment, etc.

Key 10: in April 2014, the company will jointly invest with Baoan, the controlling shareholder of the company, to establish Shenzhen baolitong micro loan Co., Ltd. The registered capital of small loan company is RMB 300 million. Among them, Baoan, China, as the main sponsor, subscribed to the registered capital of 213million yuan, and held 71% of the equity of small loan companies; The company contributed 87million yuan, with 29% of the equity of small loan companies. The company said that the establishment of small loan companies is in line with the national policy guidance, has a broad market prospect, and is conducive to improving the efficiency of the company's capital use and increasing shareholder returns[ 1]

>>ATOP ring oil pump jack for sale electrical submersible pump manufacturers